Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tasha Elswick

Physician Assistant Winfield, WV Physician Assistant

NPI 1356307243 CMS profile 10614778

192 Baker Dr, Winfield, WV 25213

Open in the dashboard

General payments

$14,490

914 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tasha Elswick of Winfield, WV is reported in the CMS Open Payments database as having received $14,490 across 914 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $317 16
2024 General $3,845 219
2023 General $3,636 233
2022 General $3,523 237
2021 General $3,170 209

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tasha Elswick
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Tasha Elswick were reported at $317. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Tasha Elswick Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,170 $132 $37–$438 $132
2022 $3,523 $155 $48–$522 $149
2023 $3,636 $167 $52–$557 $160
2024 $3,845 $178 $55–$600 $164
2025 $317 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,949 153 payments
  2. AstraZeneca Pharmaceuticals LP $1,592 79 payments
  3. AbbVie, Inc. $1,540 102 payments
  4. Amgen Inc. $1,372 90 payments
  5. Lilly USA, LLC $877 60 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $742 52 payments
  7. GlaxoSmithKline, LLC. $666 43 payments
  8. Pfizer Inc. $450 29 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $406 36 payments
  10. Janssen Pharmaceuticals, Inc $343 22 payments
  11. Other $4,553 248 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,490 914 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,535 123 payments
  2. RYBELSUS $1,517 122 payments
  3. Repatha $936 70 payments
  4. UBRELVY $869 51 payments
  5. FARXIGA $700 38 payments
  6. Otezla $626 63 payments
  7. QULIPTA $561 37 payments
  8. NURTEC ODT $552 34 payments
  9. BREZTRI $532 25 payments
  10. TRADJENTA $440 33 payments
  11. Other $12,031 738 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 98 drugs

Part D claims

4,180

Median for Physician Assistant: 241

Drug cost

$500,826

Median for Physician Assistant: $4,110

Branded share of claims

18%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 51 $77,735
Ozempic Semaglutide Brand 25 $53,979
Eliquis Apixaban Brand 33 $53,209
Repatha Sureclick Evolocumab Brand 37 $47,596
Farxiga Dapagliflozin Propanediol Brand 28 $43,368
Xarelto Rivaroxaban Brand 27 $38,583
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $28,988
Tresiba Flextouch U-200 Insulin Degludec Brand 15 $26,597
Januvia Sitagliptin Phosphate Brand 13 $21,704
Tresiba Flextouch U-100 Insulin Degludec Brand 20 $18,276

The 10 drugs with the highest cost, of 98 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$33,387

Of which drugs: $3,256

Medicare patients

212

Average age 74

Services billed

737

140 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 43%
Chronic kidney disease 43%
Depression 42%
Diabetes 35%
COPD 25%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 25 25 $2,046

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$388 — —
Ozempic
$233 25 —
RYBELSUS
$212 — —
VOQUEZNA
$179 — —
Kerendia
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

914 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record